DJIA 17,678.23 -40.31 -0.23%
NASDAQ 4,863.36 -13.16 -0.27%
S&P 500 2,056.15 -4.90 -0.24%
market minute promo

7.25 0.33 (4.77%)

REAL-TIME: Last trade at

Extended Hours: $8.03 $0.78 (10.76%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

OREX $7.25 4.77%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.89
Previous Close $6.92
Daily Range $6.64 - $7.47
52-Week Range $3.11 - $9.37
Market Cap $897.0M
P/E Ratio -21.63
Dividend (Yield) $0.00 (0.0%)
Volume 9,115,826
Average Daily Volume 8,144,585
Current FY EPS -$0.68




Drug Makers

Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary

Biotech Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers insight on three biotech stocks, including two that investors should stay away from.

Benzinga's Top #PreMarket Gainers

Orexigen - Honeymoon Continues With European Approval Of Anti-Obesity Drug

Oxford Industries, Orexigen And GameStop Lead Thursday's After-Hours Movers

Orexigen: Contrave Gathering Momentum

Vivus, Arena, Or Orexigen - Which Will Win The Anti-Obesity Market Share Race?

Orexigen Therapeutics (OREX) Showing Signs Of A Dead Cat Bounce Today

Best One-Drug Wonder Stock for 2015

You've got to start somewhere. Here's our top picks of biotechs with just one drug on the market.

Orexigen - Contrave Scripts Up, Equity Down, Approval In Europe Still Not Announced

Arena: Belviq Scripts See Modest Rise, Revenue Story Not Promising

See More OREX News...

OREX's Top Competitors

OREX $7.25 (4.77%)
Current stock: OREX
AMGN $160.55 (-0.04%)
Current stock: AMGN
GILD $101.08 (1.22%)
Current stock: GILD
BIIB $429.09 (-0.59%)
Current stock: BIIB